What if you found cancer early enough to make a difference?

The Galleri multi-cancer early detection test from GRAIL can screen for more than 50 types of cancer by looking for a shared cancer signal and pointing to where in the body a signal may be coming from. The Galleri test is the latest groundbreaking innovation added to the John Hancock Vitality Program.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Galleri Lifestyle Shot10 4043

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests.

Patient Testimonial

Hear From Kelley
Cancer Signal Detected

The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. False positive and false negatives results can occur. It should be used in addition to screening tests your healthcare provider recommends.

Jhvaccess testimonial

Not registered for John Hancock Vitality yet?

You need to activate your Vitality account before you can request your Galleri test.

Activate Today

Key benefits of the Galleri test

hourglass icon

Early cancer detection

Detects many cancers not commonly screened for today, to allow for earlier treatment.1

stethoscope icon

Testing with ease

Completed with a simple blood draw.

blue test result icon

Actionable results

If a cancer signal is found, the results can point to where in the body the cancer may be coming from with high accuracy.

The Galleri test is a screening test and does not detect all cancers.
Further testing is needed to diagnose cancer if a signal is detected.

Who is eligible?

Eligibility requirements

John Hancock is offering access to the Galleri test to registered Vitality PLUS members who have completed the Vitality Health Review in the current program year. Test eligibility is also subject to GRAIL’s clinically informed criteria, as well as additional cancer risk factors for those ages 40-49. You must be:

  • At least 50 years old
    OR
  • 40-49 years old with certain risk factors for cancer*

Availability may vary by state.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

The Galleri testing process

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

Get started by creating a Galleri portal account and completing an online test request which includes questions about your medical history (about 10 minutes).

Important: To create an account, you will need to input your Access ID provided in the offer email you received from John Hancock Vitality.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine physician confirms you are eligible and orders Galleri, you will receive a notification via email. Then, you can schedule a blood draw at one of GRAIL’s blood draw partners. You will receive a collection kit in the mail to take with you to your appointment.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

The trained technician that draws your blood sample will ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will reach out when your results are ready - about 2 weeks after your blood is received at the GRAIL laboratory. Your test result will be shared with you by Recuro Health.

Please note, your test results will not be shared with John Hancock or Vitality and results will have no impact on your current life insurance coverage.

Important information about your results:

False positive and false negative results do occur. The Galleri test does not detect all cancers. Not all cancers can be detected in the blood.

Keep in mind that you will not receive a list of the 50+ types of cancer Galleri can screen for and a result for each one.

The Galleri test does not measure your genetic risk of developing cancer in the future. It’s important to continue with any additional screenings your healthcare provider recommends. The Galleri test is currently not approved by the U.S. Food and Drug Administration.

How to take the test?

Galleri is a multi-cancer early detection (MCED) test that looks for a cancer signal across more than 50 types of cancer. It's a screening test, which means that while it does not diagnose cancer, it can improve your chance of finding it early.

About the test
About the results
How To Take The Test Telemed

Patient Testimonial

Hear From Roger
Cancer Signal Detected

Roger is not a John Hancock Vitality member.

Roger testimonial

Frequently Asked Questions

John Hancock is offering access to the Galleri test to registered Vitality PLUS members who have completed the Vitality Health Review in the current program year. Test eligibility is also subject to GRAIL’s clinically informed criteria, as well as additional cancer risk factors for those ages 40-49. You must be:

  • At least 50 years old

    OR

  • 40-49 years old with certain risk factors for cancer
    • At least one of the following risk factors:
      • Cancer survivor who has completed treatment at least 3 years ago*
      • Currently smokes or quit smoking less than 10 years ago
      • Diagnosis of cirrhosis or chronic Hepatitis B or C infection
      • Infection with certain strains of HPV (e.g., HPV 16 or 18)
      • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, CHEK2)

        OR

    • At least two of the following risk factors:
      • Documented genetic predisposition (germline variant)
      • First degree relative with cancer*
      • History of HIV infection
      • Current use of immunosuppressive therapies after organ transplantation
      • Diabetes
      • Elevated BMI:
      • Female ≥ 30
      • Male ≥ 35

Please note: Galleri is not recommended by GRAIL for individuals who are pregnant or undergoing active cancer treatment.

*Excludes basal or squamous cell carcinoma of the skin

The Galleri test is designed to detect many cancers that are not commonly screened for today which can allow for earlier diagnosis and consideration of more treatment options. A positive Galleri test result should be followed by an appointment with your primary care physician and appropriate diagnostic tests to confirm cancer status. There may be additional costs for such diagnostic testing.

The cost of the Galleri test depends on the coverage amount of your insurance policy. Please refer to the John Hancock Vitality app or website to confirm your cost of the Galleri test.

  • Eligible members with policies less than $500,000 are responsible to pay $475 – 50% off the retail price.
    GRAIL will bill you after you have received your results
  • Eligible members with policies greater than or equal to $500,000 can access the test at no cost
  • Please note: if you have multiple policies, the policy with the highest face amount will determine the subsidy amount of the Galleri offer

If you choose to complete the blood draw at a lab not on GRAIL’s approved partner list, including your primary healthcare provider’s office, you will be responsible for the blood draw fee per your health insurance provider’s requirements.

In the event of a “Cancer Signal Detected” test result, you will be responsible for the cost of follow-up diagnostic procedures (e.g., imaging, biopsies, other laboratory tests, etc.). You may incur cost share expenses such as co-pays, deductibles, and co-insurance with your health insurance provider. Please contact your health insurance plan to determine covered expenses and your potential costs related to follow-up procedures that your healthcare provider may recommend.

There is no coordination of benefits between John Hancock and any health benefits you may receive from an insurance policy, health plan, or any other wellness programs you may be enrolled in.

The tax treatment of the Galleri test offered in connection with the Vitality Program is uncertain. At this time, John Hancock does not expect that it will be required to report the value of the Galleri test to the IRS as income to the insured. You should consult your own tax professional.

John Hancock Vitality members who have an Access ID through the Vitality app or website can request the test through GRAIL’s patient portal, via Galleri.com/JHVAccess.

Once you complete the online test request form, a healthcare provider from Recuro Health, an independent telemedicine provider partnered with GRAIL, will review your request and clinical eligibility within one week. A Recuro Health physician will approve your request and order the test, if appropriate.

To be eligible for this offer, John Hancock Vitality PLUS members must request their test on the John Hancock Galleri web page using their unique Galleri Access ID (available on the Vitality app or website). However, members may consult with their primary care physician in advance if they have questions.

Once the member requests the test, a physician from Recuro Health, an independent telemedicine provider partnered with GRAIL, will review your request and order the test, if appropriate.

When you request the test, Recuro Health gives you the option to enter your primary healthcare provider's contact information, so that Recuro Health can automatically share your results if the test result is "cancer signal detected". If the test result is "no cancer signal detected," you can share the results with your provider, but results will not be sent by Recuro Health to anyone other than you.

The Galleri test is only available to John Hancock members whose eligibility is evaluated and confirmed by Recuro Health, an independent telemedicine provider partnered with GRAIL (see Question #1 above for additional information).

If you are not eligible under the terms of John Hancock ’s offer (i.e., due to policy issue state) but would still like to learn more about the test, visit Galleri.com. The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. You would be responsible for the cost of the test and provider services.

The Galleri test is currently available to John Hancock Vitality members whose eligibility is evaluated and confirmed by Recuro Health, an independent telemedicine provider partnered with GRAIL (see Question #1 above for additional information).

Other family members are not eligible for this John Hancock offer but may learn more about the test and request it at Galleri.com. The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The family member would be responsible for the cost of the test and provider services.

John Hancock is committed to helping its customers live longer, healthier, better lives by offering them the latest tools and technology that can help them better understand their health and make informed choices.

The Galleri test is designed to detect many cancers that are not commonly screened for today, to allow for earlier diagnosis and treatment. John Hancock wants to make customers aware of the technology so that they can decide if taking the test is right for them.

John Hancock and Vitality will not receive individual test results and results will have no impact on your current life insurance coverage.

As part of this offer, eligible John Hancock Vitality members are limited to one Galleri test.

The Galleri test is a multi-cancer, early detection test that uses a single blood draw to screen for more than 50 types of cancer, many of which are not commonly screened for today. The Galleri test does not diagnose cancer and not all cancers may be detected in the blood.

The Galleri test is intended to be used in addition to, and not in lieu of, other cancer screening tests your healthcare provider recommends.

The Galleri test does not detect all cancers, nor does it measure your genetic risk of developing cancer in the future. A test result of “Cancer signal not Detected” does not rule out cancer, and in particular, the sensitivity rate for detecting cancer in the early stages is lower than for later stages.

The Galleri test looks for signals present in the blood that may be associated with cancer at the time of your blood draw. If a cancer signal is detected, the results can point to where in the body the cancer signal is coming from to help your healthcare provider guide next steps.

Family history is only one of many risk factors associated with cancer development. Other risk factors include eating habits, lifestyle, living or working environments, genetics, and many others.

When you submit your test request, you may ask for a pre-test consultation with a Recuro Health provider to discuss whether the test is right for you. This optional consultation is included in the offer. Additionally, we suggest speaking with your primary care physician.

Your test results will not impact your premiums or risk class on your current (inforce) policies, either positively or negatively. Results will also not impact your Vitality Status.

Like other medical tests you elect, a decision to take the Galleri test, and the results of the test, may need to be disclosed in an application for insurance coverage, and so could affect your access to future insurance coverage and the price of such coverage.

If an individual receives a “cancer signal detected” result from the Galleri test and follow-up diagnostic testing confirms a cancer diagnosis, it could impact insurability or premiums if they subsequently apply for additional life insurance coverage — as is the case with a cancer diagnosis that results from many other commonly used diagnostic tools that are reviewed during the underwriting process.

If an individual receives a “cancer signal detected” result but does not follow up with their physician and then applies for additional coverage, John Hancock would request appropriate clinical follow up with the insured’s physician, consistent with standard underwriting practices.

Existing cancer or cancer that is in remission would need to be disclosed in most insurance applications. This does not necessarily mean that new policy applications would be declined or require higher premiums.

In a clinical validation study (CCGA3*), the Galleri test detected more than 50 types of cancer across all stages.

*Circulating Cell-Free Genome Atlas (CCGA) sub-study

The Galleri test is intended to be used in addition to and not replace other cancer screening tests and can help maximize the benefits of early cancer detection. Missing recommended screenings or ignoring symptoms could lead to a delayed diagnosis of cancer.

Based on data from GRAILS’s studies, the Galleri test has shown a low false positive rate of 0.5% in non-cancer participants (detects a cancer signal when no cancer is present). This means in the clinical studies, in approximately 200 non-cancer participants, 1 participant received a positive (false positive) test.

The Galleri test development was supported by what is believed to be one of the largest clinical study programs in genomic medicine, with over 20,000 participants at more than 140 clinical study sites, including the Mayo Clinic, Dana-Farber Cancer Institute, Cleveland Clinic, Sutter Health, OHSU, Intermountain Healthcare, and U.S. Oncology Network.

The Galleri test has not been cleared or approved by the FDA. GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing.

You need your unique Galleri Access ID. If you are eligible for the offer, your Access ID is available on the Vitality app or website. If you cannot locate your ID, please contact John Hancock Vitality at 888-333-2659. You cannot request your test at Galleri.com/JHVAccess without your Galleri Access ID.

A physician from Recuro Health, an independent telemedicine provider partnered with GRAIL, will review your request and clinical eligibility within one week. They will approve your request and order the test, if appropriate.

If the Recuro Health physician approves your request, you will be shipped a Galleri collection kit and will receive an email confirmation with instructions for how to schedule your blood draw.

When your collection kit arrives, you can schedule a blood draw appointment at one of GRAIL’s partner labs or mobile phlebotomy providers. Test results will be ready about two weeks after your sample is received at GRAIL.

If your Galleri test request is approved and your collection kit has arrived, you can schedule a blood draw appointment with one of GRAIL’s partner labs or mobile phlebotomy provider.

Please note that completing your blood draw at some place other than one of GRAIL’s partner labs will not be covered by this offer.

Bring your unopened Galleri sample collection kit and your completed and printed ‘Test Requisition Form’ to your blood draw appointment.

You will receive these items if your eligibility for the Galleri test is approved. A collection kit will be mailed to you within one week after your request is approved. Do not break the quality seal on the collection kit. It should be opened by the lab technician who draws your blood sample. A completed Test Requisition Form will be emailed to you from GRAIL. Remember to print the form and bring it to your appointment.

The Test Requisition Form (TRF) is the ordering form Recuro Health completes to order the test for you.

You will receive this document via an order confirmation email from GRAIL if the provider orders your test.

No preparation or fasting is required. Some lab technicians may ask if you have fasted (no eating or drinking), but this is not required for the Galleri test.

Please do not break the quality seal on the collection kit. It should be opened by the lab technician who draws your blood sample.

Store the collection kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, avoid storing your collection kit in the trunk of your car.

Your next step is to schedule your blood draw at a GRAIL partner lab. There is also a mobile phlebotomy option.

The collection kit includes instructions for the lab technician, two tubes for the blood sample, and packing materials to ensure the sample is safely shipped to GRAIL.

Please do not break the quality seal on the collection kit. It should be opened by the lab technician who draws your blood sample.

The lab technician who draws your blood will pack and ship your sample back to GRAIL for processing.

Your sample will arrive at GRAIL 1 to 2 business days after your blood draw.

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes typically from a vein in your arm.

It takes about two weeks after your blood sample is received at the GRAIL laboratory to receive your Galleri test results from the Recuro Health provider that ordered your test.

Your sample will arrive at the GRAIL lab one to two business days after your blood draw. Your results should be available to the Recuro Health provider who ordered your test within 10 business days (Mon - Fri excluding holidays) from the time your sample is received at GRAIL.

If you no longer wish to receive your Galleri results, please ccontact Recuro Health to request a cancellation atmemberservices@recurohealth.com or 1-833-691-1714.

If you require further assistance, please contact GRAIL Customer Service at customerservice@​grail.​com.

This means that no cancer signal was found. However, the Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Continue with all routine screening tests that your healthcare provider recommends. Missing routine screenings or ignoring symptoms can lead to a delayed diagnosis of cancer.

Recuro Health also offers optional post-test counseling to discuss your result, which is included in your offer.

This means a signal often associated with cancer was found and additional tests are needed to confirm if you have cancer. The Recuro Health physician who ordered your test will share this result with you and what it may mean.

When you request the test, you are given the option to enter your primary healthcare provider's contact information, so that Recuro Health can automatically share your result if a cancer signal is detected. If you do not have a primary healthcare provider, GRAIL’s Patient Advocate can help you find one in your area.

The Galleri test will include a prediction of the cancer signal origin (tissue type or organ associated with the cancer signal) to help guide your primary healthcare provider in the next steps. Diagnostic testing by a healthcare provider is needed to confirm if you have cancer.

In the event that a diagnostic evaluation after a “cancer signal detected” result with Galleri does not confirm cancer, you may be eligible for a complimentary Galleri re-test directly from GRAIL.

The request for a re-test must be placed by the healthcare provider managing your diagnostic evaluation. The re-test must be administered within 3-6 months after the initial Galleri test.

To initiate a request for a re-test, your healthcare provider should contact GRAIL Customer Service at 833-MY-GALLERI (833-694-2553) or customerservice@grail.com. John Hancock does not pay for re-tests due to a false positive.

Galleri is a test that screens for the presence of cancer in the blood and provides information on where in the body the cancer may be located. The Galleri test is not a diagnostic test. Additional tests ordered by your primary healthcare provider are needed to confirm if cancer is present — which may include blood work, imaging, or certain invasive procedures.

In the event of a “Cancer Signal Detected” test result, this offer from John Hancock Vitality does not cover or pay for follow-up diagnostic procedures (e.g., imaging, biopsies, other laboratory tests, etc.). You may incur cost share expenses such as co-pays, deductibles, and co-insurance from your health insurance provider. Please contact your health insurance plan to determine covered expenses and your potential costs related to follow-up procedures that your healthcare provider may recommend.

There is no coordination of benefits between John Hancock and any health benefits you may receive from an insurance policy, health plan, or any other wellness programs you may be enrolled in.

Yes, when you request the test, Recuro Health gives you the option to enter your primary healthcare provider's contact information so that your test results can be shared if a cancer signal is detected.

Recuro Health will not automatically share a No Cancer Signal Detected result, but we encourage you to share it with your primary healthcare provider.

The prescribing healthcare provider from Recuro will receive the results and share them with you. Your results and medical information are confidential, and access is limited to individuals who need the information for a specific purpose.

For example, if a cancer signal is detected, Recuro will share your Galleri test result with your primary healthcare provider only if you gave their contact information so that they can guide your next steps.

John Hancock does not receive individual test results from GRAIL, nor does it know which customers have requested or taken the test. Your results will have no impact on your current life insurance coverage. For purposes of research, validation of assumptions and evaluation of future health and wellness offerings, John Hancock may receive aggregated and deidentified data from GRAIL from time to time.

Still have questions?

Here’s who to contact:

For eligibility and Access ID questions or privacy concerns, please contact Vitality Customer Care at 888−333−2659 (8am — 6pm EST) or email support@​jhvitality.com.

For all other questions (e.g., ordering the test, receiving the test, getting the blood draw, or test results), please contact GRAIL Customer Service at 833−694−2553 (8am — 8pm EST M‑F) or email customerservice@​grail.​com.

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

John Hancock does not provide medical advice, is not involved in the design or manufacture of the Galleri test and is not responsible for the accuracy or performance of the Galleri test. A test result of ​“Cancer Signal Not Detected” does not rule out cancer, and in particular the sensitivity rate for detecting cancer in early stages is lower than for later stages. Galleri does not replace routine cancer screenings. Galleri is not a test to rule out genetic or other conditions that may indicate a predisposition to cancer. There is no coordination between John Hancock and any health insurance or other benefits plan you may be enrolled in. You may incur additional costs for diagnostic screenings recommended by your healthcare provider.

Like other medical tests you elect, a decision to take the Galleri test, and the results of the test, may need to be disclosed in an application for insurance coverage, and so could affect your access to future insurance coverage and the price of such coverage.

John Hancock does not receive individual test results from GRAIL, nor does it know which customers have requested or taken the test. Your results will have no impact on your current life insurance coverage. For purposes of research, validation of assumptions and evaluation of future health and wellness offerings, John Hancock may receive aggregated and deidentified data from GRAIL from time to time.

The tax treatment of the Galleri test offered in connection with the Vitality Program is uncertain. At this time, John Hancock does not expect that it will be required to report the value of the Galleri test to the IRS as income to the insured. This material does not constitute tax or legal advice and neither John Hancock nor any of its agents, employees or registered representatives are in the business of offering such advice. You should consult your own tax professional.

The Galleri test is only available to registered John Hancock Vitality PLUS members who are 40 years of age or older and have completed the Vitality Health Review (VHR) for the current Program Year. For eligible polices with coverage amounts of $500,000 or greater, 100% of the cost of the test will be subsidized. For policies with less than $500,000 in coverage, 50% of the cost of the test will be subsidized. Test eligibility is also subject to GRAIL’s clinically informed criteria, as well as additional cancer risk factors for those ages 40-49. Please note: for members with multiple policies, the policy with the highest face amount will determine the subsidy amount of the Galleri offer. The offer of discounted access to the Galleri test is subject to change. Availability of the Galleri test offer from John Hancock may vary by state.

Vitality is the provider of the John Hancock Vitality Program in connection with policies issued by John Hancock. John Hancock Vitality Program rewards and discounts are available only to the person insured under the eligible life insurance policy, may vary based on the type of insurance policy purchased and the state where the policy was issued, are subject to change and are not guaranteed to remain the same for the life of the policy. Life insurance policies and/​or associated riders and features may not be available in all states.

Insurance products are issued by: John Hancock Life Insurance Company (U.S.A.), Boston, MA 02116.

©2023, GRAIL, LLC. ALL RIGHTS RESERVED. GALLERI IS A TRADEMARK OF GRAIL, LLC. John Hancock is not an affiliate of GRAIL. All product and company names are the trademarks of their original owners. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder or its product brand.

MLI051524530-1

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.